• Science & evidence
• Safety and quality
• FDA

Melanotan II, the "tanning peptide": what the Arizona research found, its two FDA-approved cousins, and where FDA stands

By Peptide Policy Watch staff · Published November 8, 2026 · 8 min read · 19 sources, 19 checked at the source

It started in a university lab in Tucson with a simple idea: if a hormone tells skin cells to make pigment, could a sturdier lab-made version produce a tan without the sun? Melanotan II came out of that work in the 1990s. Today the name turns up in tanning forums and gym chats, and on FDA's list of compounding substances it has safety questions about. Two close relatives took a very different road. Both are FDA-approved prescription medicines.

Facts are as of November 8, 2026. Sources, with retrieval dates, are at the bottom.

Where the idea came from

Your skin's color comes mostly from melanin, made by cells called melanocytes. A natural hormone, alpha-melanocyte-stimulating hormone (alpha-MSH), switches that process on through a receptor called MC1R. Chemists at the University of Arizona set out to build lab-made versions of it. Melanotan II is a short, cyclic one, closed into a ring by a lactam bridge, which the team described in 1996 as "superpotent" in lab tests. [V] A 2012 toxicology case report sorts the family into three: melanotan I for tanning, melanotan II for tanning plus sexual effects, and bremelanotide, which it calls a variation of melanotan II built for sexual stimulation. [V]

What the human studies showed

The research record is small, early-stage and genuinely interesting. Here is what the published studies reported, each labeled by evidence level.

The first pilot study (1996, 3 men, single-blind, placebo-controlled). Dorr and colleagues in Life Sciences gave melanotan II or saline on alternating days for two weeks. Two of the three volunteers showed increased pigmentation on the face, upper body and buttocks, measured by reflectance a week after the study ended. The authors concluded it has tanning activity in humans. They also reported mild nausea, sleepiness and fatigue at the higher levels tested, and a stretching-and-yawning pattern that tracked with spontaneous erections. [V] (Small human pilot study.)

The surprise finding becomes its own study (1998, 10 men, double-blind crossover). Because of those erections, the Arizona group tested melanotan II in men with erectile dysfunction that had no known physical cause. In the Journal of Urology, 8 of 10 men developed clinically apparent erections on melanotan II. Average time at more than 80% tip rigidity was 38.0 minutes on the peptide versus 3.0 on placebo. Nausea, yawning and reduced appetite were more common on the peptide. [V] (Small randomized crossover trial.)

A second trial in men with physical risk factors (2000, 10 men). In Urology, erections followed 12 of 19 melanotan II administrations versus 1 of 21 placebo. Reported sexual desire was also higher after the peptide, and 4 of 19 administrations came with severe nausea. The authors said that desire finding deserved more study of brain-acting drugs. [V] (Small randomized crossover trial.)

That last line turned out to be a signpost.

The two cousins that made it

Bremelanotide (Vyleesi). Palatin Technologies developed a peptide called PT-141. Its researchers described it in 2003 as a synthetic alpha-MSH analog that acts mainly on the MC3 and MC4 receptors in the brain. [V] Put the two published structures side by side and they are almost the same molecule. Vyleesi's label lists bremelanotide as a seven-unit ring of amino acids that ends in a free acid group. The 1996 paper lists the same sequence for melanotan II, with an amide group at the end instead. [V] That's our comparison of the two published structures. FDA approved Vyleesi on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The approval rested on two 24-week randomized, placebo-controlled trials in 1,247 women. [V] About 25% of women on Vyleesi had a meaningful rise in their desire score, against about 17% on placebo. [V]

Afamelanotide (Scenesse). Scenesse's label describes afamelanotide as a synthetic peptide of 13 amino acids that activates MC1R, the same skin-pigment receptor. [V] FDA approved it on October 8, 2019, for adults with erythropoietic protoporphyria, calling it the first drug meant to lengthen the time they can spend in light without pain. EPP is a rare disorder in which sunlight causes intense skin pain. [V] In the first of two placebo-controlled trials, the median time spent in direct sunlight on pain-free days over 180 days was 64 hours on Scenesse versus 41 on placebo. [V] It's an implant given by a trained health care professional, and its label recommends a full-body skin check twice a year. [V]

So the same family of molecules produced two approved medicines for narrow, well-defined conditions, each backed by randomized trials. Melanotan II itself never went through that process.

• 2FDA-approved drugs from the same peptide family [V]
• 1,247women in Vyleesi's two main trials [V]
• 3volunteers in the first melanotan II human study, 1996 [V]

Where melanotan II stands with FDA

Approval. There is no FDA-approved drug containing melanotan II. Drugs@FDA lists Scenesse and Vyleesi as prescription products. [V] Products sold online as "melanotan" are not those drugs.

Compounding. Compounding pharmacies can only use certain bulk ingredients. Someone nominated melanotan II for the 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry bulks list, and that nomination was later withdrawn. FDA's page of bulk substances that may present significant safety risks lists it in its "nominated but withdrawn" table. [V] Our explainer on FDA's compounding categories covers what those tables mean.

FDA's entry also flags a possible immune-reaction risk for some routes, from aggregation or peptide-related impurities, and lists posterior reversible encephalopathy syndrome, a sympathomimetic toxidrome and priapism among the case reports. [V]

The next advisory meeting. FDA's Pharmacy Compounding Advisory Committee page lists melanotan II among five substances to be considered for the 503A bulks list, alongside LL-37, GHK-Cu, dihexa acetate and PEG-MGF. FDA says it will hold that meeting before the end of February 2027. As of November 8, it had not posted a date or place. [V] Committee votes are advice, not law. In July 2026 the same committee backed six peptides FDA staff had recommended against, and HHS later drafted a compounding policy for those six. [S] Our preview of the next meeting has the full agenda, and our 503A bulks list explainer shows how a substance gets on.

Limits and unknowns

The safety record outside trials comes mostly from case reports, and a case report can't prove a peptide caused what happened. They are still the signal FDA cites, so here they are.

• Melanoma. A 2014 Dermatology report described melanoma in a 20-year-old woman who had used melanotan II alongside tanning beds. [V] A 2025 report described an oral mucosal melanoma in a 22-year-old who had used a melanotan II nasal spray for tanning. [V] A 2026 report described five melanomas in situ in a patient who had used tanning beds, melanotan and anabolic hormones. [V]
• Brain swelling syndrome (PRES). A 2013 letter in Annals of Internal Medicine linked melanotan use to posterior reversible encephalopathy syndrome. [V]
• Whole-body toxicity. A 2012 Clinical Toxicology case described a man who developed sympathomimetic symptoms, severe muscle breakdown and kidney strain after using melanotan II bought online. Lab testing confirmed the product was melanotan II. [V] A 2013 letter in the same journal reported priapism. [V]
• What's in the vial. Products sold outside pharmacies have no FDA quality check, so content and purity are unknown. Our label decoder explains what "research use only" does and doesn't mean. [U]
• Approved cousins have warnings too. Vyleesi's label warns of temporary blood pressure rises, nausea in about 40% of trial patients, and darkening of the face, gums or breasts in about 1%. Scenesse's label warns of serious allergic reactions, including anaphylaxis, and darkening of moles and freckles. [V]

The human trials of melanotan II itself total a few dozen people, all men, from more than 25 years ago. Nobody has published a large controlled trial of it for tanning. [U] That's our reading of the PubMed record as of today.

What to watch

The advisory meeting is the date that matters. When FDA posts briefing documents, they'll show the agency's full safety review of melanotan II, and the committee will vote. For how this peptide family fits the wider picture, our page on approved peptide medicines versus wellness peptides is a good next read, and the evidence ladder explains why three volunteers and two approved drugs sit on very different rungs.

Sources (retrieved November 8, 2026)

1. Dorr RT et al., "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study," Life Sciences 1996;58(20):1777-84, PMID 8637402 [V] — https://pubmed.ncbi.nlm.nih.gov/8637402/
2. Wessells H et al., "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction," Journal of Urology 1998;160(2):389-93, PMID 9679884 [V] — https://pubmed.ncbi.nlm.nih.gov/9679884/
3. Wessells H et al., "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction," Urology 2000;56(4):641-6, PMID 11018622 [V] — https://pubmed.ncbi.nlm.nih.gov/11018622/
4. Molinoff PB et al., "PT-141: a melanocortin agonist for the treatment of sexual dysfunction," Annals of the New York Academy of Sciences 2003;994:96-102, PMID 12851303 [V] — https://pubmed.ncbi.nlm.nih.gov/12851303/
5. FDA, "FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women," June 21, 2019 (FDA release as distributed on PR Newswire) [V] — https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-hypoactive-sexual-desire-disorder-in-premenopausal-women-300872998.html
6. FDA, Vyleesi (bremelanotide) approval package, NDA 210557, approved June 21, 2019 [V] — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf
7. Vyleesi prescribing information via openFDA drug label API (label effective November 13, 2025) [V] — https://api.fda.gov/drug/label.json?search=openfda.generic_name:bremelanotide
8. FDA, "FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder," October 8, 2019 (FDA release as distributed on PR Newswire) [V] — https://www.prnewswire.com/news-releases/fda-approves-first-treatment-to-increase-pain-free-light-exposure-in-patients-with-a-rare-disorder-300934079.html
9. FDA, Scenesse (afamelanotide) approval package, NDA 210797, approved October 8, 2019 [V] — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000Approv.pdf
10. Scenesse prescribing information via openFDA drug label API (label effective May 11, 2026) [V] — https://api.fda.gov/drug/label.json?search=openfda.generic_name:afamelanotide
11. openFDA Drugs@FDA records for NDA 210797 and NDA 210557 (marketing status Prescription) [V] — https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:afamelanotide+bremelanotide
12. FDA, "Certain bulk drug substances for use in compounding that may present significant safety risks," content current as of April 22, 2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
13. FDA, "Meeting of the Pharmacy Compounding Advisory Committee," content current as of April 15, 2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
14. Hjuler KF, Lorentzen HF, "Melanoma associated with the use of melanotan-II," Dermatology 2014;228(1):34-6, PMID 24355990 [V] — https://pubmed.ncbi.nlm.nih.gov/24355990/
15. Yassin Alsabbagh A et al., "Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?" Int J Oral Maxillofac Surg 2025;54(9):806-808, PMID 40210573 [V] — https://pubmed.ncbi.nlm.nih.gov/40210573/
16. Vadner DJ et al., "Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use," JAAD Case Reports, July 2026, PMID 42328529 [V] — https://pubmed.ncbi.nlm.nih.gov/42328529/
17. Kaski D et al., "Melanotan and the posterior reversible encephalopathy syndrome," Annals of Internal Medicine 2013;158(9):707-8, PMID 23648958 [V] — https://pubmed.ncbi.nlm.nih.gov/23648958/
18. Nelson ME et al., "Melanotan II injection resulting in systemic toxicity and rhabdomyolysis," Clinical Toxicology 2012;50(10):1169-73, PMID 23121206 [V] — https://pubmed.ncbi.nlm.nih.gov/23121206/
19. Devlin J et al., "Melanotan II overdose associated with priapism," Clinical Toxicology 2013;51(4):383, PMID 23537392 [V] — https://pubmed.ncbi.nlm.nih.gov/23537392/

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits